• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment

Monday, June 03, 2024
Breakout Session
Business Development and Finance
32AB
The 34th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth quantitative and qualitative look at the US and European biotechnology industry’s standing within a complex financing, regulatory and fast evolving healthcare environment. Despite a near closure of the IPO window and a difficult venture capital raising landscape following the sugar high during the pandemic, the start-up innovation engine of the pharmaceutical ecosystem continues to produce novel treatments. Biotech’s are advancing novel molecular entities – many enabled by new technologies such as cell and gene therapies, mRNA, Antibody-Drug Conjugates (ADC), CAR-T, while using generative AI/ML to create efficiencies in the process. We will explore these current topics – and more – during the Beyond Borders session.
Moderator
Arda Ural, PhD
Americas Leader for Life Sciences and Healthcare
EY (Ernst & Young)
Speakers
Chris Garabedian
CEO
Xontogeny
Barbara Ryan
Board Member
Indivior, Mink, OccuTerra, Invo, SafeCor Pharmaceutical Companies
Brian Bronk, PhD
Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms
Sanofi
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS